InnoCare and Eli Lilly strike research collaboration worth up to $3.35B

What's the deal? InnoCare Pharma, a Chinese biopharmaceutical company focused on cancer and autoimmune diseases, has signed a strategic research collaboration and licence agreement with Eli Lilly to discover and develop new medicines. Under the deal, announced on ️24 September ️2026, InnoCare will use its proprietary drug-discovery platform to advance compounds against up to five undisclosed targets, and could receive up to $100 million in upfront and near-term payments, up to roughly $3.25 billion in development and commercial milestone payments, plus single-digit tiered royalties on annual net product sales, putting the total potential value at about $3.35 billion.

Why it matters: The agreement hands Lilly access to InnoCare's discovery engine at a time when big pharma is increasingly buying or licensing Chinese biotech innovation, and gives InnoCare — which already has three approved drugs and ten-plus clinical candidates in its pipeline — a major source of non-dilutive funding and validation from one of the world's largest drugmakers. For Lilly, it adds another string to its early-stage R&D bow without the risk of fully owning the discovery work. The companies did not disclose the disease areas or specific targets involve, beyond InnoCare's stated focus on oncology and immunology.

InnoCare, listed in Hong Kong and Shanghai, has built platforms for drug discovery across small molecules and other modalities, and says it will dedicate its teams and infrastructure to moving the collaboration's programmes toward clinical candidates.

Read more: GlobeNewswire (via Markets Insider(, 24 September ️2026